Nantahala Capital Partners Reports 5.82% Stake in Abeona Therapeutics Inc.

Nantahala Capital Partners Limited Partnership filed a Schedule 13G/A on May 15, 2026, reporting a new significant stake in Abeona Therapeutics Inc. (ABEO). As of the event date of March 31, 2026, the reporting person beneficially owns 3,333,757 shares of common stock, representing 5.82% of the company based on approximately 57 million shares outstanding. This holding includes 179,832 shares that may be acquired within sixty days through the exercise of securities. The filing indicates shared voting and dispositive power over all reported shares. This position marks a notable increase from the previously reported 0% ownership, crossing the 5% threshold required for beneficial ownership reporting. The filing was made under Rule 13d-1(c), certifying that the securities were not acquired for the purpose of changing or influencing the control of the issuer. Key signatories include Taki Vasilakis, Wilmot B. Harkey, and Daniel Mack of Nantahala Capital Management, LLC.